Rechercher des projets européens

19 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

Nanomedicine upscaling for early clinical phases of multimodal cancer therapy (NoCanTher)

Date du début: 1 avr. 2016, Date de fin: 31 mars 2021,

During the last four years the Multifun Consortium (FP7 project Nº. 262943) has developed and validated distinct nanoformulations as therapeutic approach against pancreatic and breast cancer. These nanoformulations are based on magnetic iron oxide nanoparticles (MNP) multifuntionalised with a target peptide and an anticancer chemical drug, allowing for a synergistic therapeutic effect produced by ...
Voir le projet

 13

 TERMINÉ 

A Phase Ib/II study of MEK1/2 inhibitor PD-0325901 or MEK-162 with cMET inhibitor PF-02341066 in RASMT and RASWT (with aberrant c-MET) Colorectal Cancer Patients (MERCURIC)

Date du début: 1 déc. 2013, Date de fin: 30 nov. 2020,

Colorectal cancer (CRC) is the 3rd most common cancer in Europe, and with approximately 200,000 deaths per year, it remains the 2nd most common cause of cancer death. More than half of all CRC patients develop distant metastases and have 5-year overall survival (OS) of less than 5% because of ineffective treatments. Increased understanding of cancer biology, coupled with the implementation of “omi ...
Voir le projet

 13

 TERMINÉ 

Deciphering PI3K biology in health and disease (Phd)

Date du début: 1 nov. 2015, Date de fin: 31 oct. 2019,

The Phosphoinositide 3-kinase (PI3K) pathway is at the core of multiple fundamental biological processes controlling metabolism, protein synthesis, cell growth, survival, and migration. This inevitably leads to the involvement of the PI3K signalling pathway in a number of different diseases, ranging from inflammation and diabetes to cancer, with PI3K pathway alterations present in almost 80% of hu ...
Voir le projet

 11

 TERMINÉ 

Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer (MoTriColor) (MoTriColor)

Date du début: 1 oct. 2015, Date de fin: 30 sept. 2019,

Colorectal cancer (CRC) is increasingly being recognized as a heterogeneous disease with distinct molecular subtypes. These subtypes have different biological processes at the basis of their disease and consequently their prognosis and responses to therapy are also different.We have previously developed molecular diagnostic assays using a single platform on routine FFPE tumour biopsies. These assa ...
Voir le projet

 12

 TERMINÉ 

Therapeutic inhibition of the oncogenic Wnt/beta-catenin pathway in mismatch repair deficient hypermutant tumors (Wnt and CRC)

Date du début: 1 sept. 2017, Date de fin: 31 août 2019,

Colorectal cancer (CRC) is a leading cause of death worldwide. Mutations in components of the canonical Wnt/beta-catenin pathway such as APC, CTNNB1/beta-catenin, AXIN2 and more recently RNF43 or ZNRF3 can contribute to CRC tumorigenesis. The hosting team and Dr. Clevers’ group have recently described that inhibitors of the porcupine enzyme, that is essential for the maturation of Wnt-ligands, hav ...
Voir le projet

 2

 TERMINÉ 

Pushing Myc inhibition towards the clinic (Mycinhibinclinic)

Date du début: 1 mai 2014, Date de fin: 30 avr. 2019,

Deregulation of the Myc oncogene promotes tumorigenesis in most if not all cancers and is often associated with poor prognosis. However, targeting Myc has long been considered impossible because of potential catastrophic side effects in normal tissues. Despite this general assumption, we showed that Myc inhibition displays extraordinary therapeutic benefit in various transgenic mouse models of can ...
Voir le projet

 2

 TERMINÉ 

Creating medically-driven integrative bioinformatics applications focused on oncology, CNS disorders and their comorbidities (MedBioinformatics) (MedBioinformatics)

Date du début: 1 mai 2015, Date de fin: 30 avr. 2018,

Progress in biomedical research and healthcare requires profiting from the huge amount of data and knowledge that are generated. However, most of the potential users have no means to efficiently exploit this wealth of information. Up to now, many of the efforts done for developing bioinformatics methods and applications have not produced the expected societal impact for different reasons, includin ...
Voir le projet

 13

 TERMINÉ 

Developing an anti-Myc cell-penetrating peptide for cancer treatment (GBM-CPP)

Date du début: 1 août 2016, Date de fin: 31 juil. 2017,

Despite ever-increasing investments in the development of new treatments, many cancers remain incurable. One reason is that most current therapies target redundant functions around which tumour cells can build resistance. We focus instead on a unique and essential cellular function: the Myc oncogene, deregulated in more than 70% of human cancers. Targeting Myc has long been considered unfeasible b ...
Voir le projet

 2

 TERMINÉ 

Rational Therapy for Breast Cancer: Individualized Treatment for Difficult-to-Treat Breast Cancer Subtypes (RATHER)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2016,

"Cancer genotyping has identified a number of correlations between mutations in specific genes and responses to targeted anti-cancer drugs, with many mutations occurring in kinases or downstream signaling components. While there are several ongoing large-scale genome re-sequencing studies for the major cancer types, there is no systematic effort to investigate kinase mutations in distinct biologic ...
Voir le projet

 8

 TERMINÉ 

Development of a more effective and safer therapeutic antibody for cancer treatment with a dual mechanism of action to eliminate CSCs and reactivate the tumour’s immune system. (CSC-IS)

Date du début: 1 juil. 2015, Date de fin: 31 déc. 2016,

Global cancer market is growing at a CAGR of 6.9% with an estimated value of $81bn in 2016. Although the huge R&D investment observed in the past years in the development of new treatments, there is still lack on an effective treatment in many tumour types. In particular, the median survival for glioblastoma multiforme (GBM), a high-grade brain tumour affecting 23,000 patients a year in US and EU, ...
Voir le projet

 2

 TERMINÉ 

A European Platform for Translational Cancer Research (EUROCANPLATFORM)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2016,

Europe has a number of advantages as regards developing translational cancer research, yet there is no clear European strategy to meet the increasing burden posed by cancer. The FP6 Eurocan+Plus project analysed the barriers underlying the increasing fragmentation of cancer research and stressed the need to improve collaboration between basic/preclinical and comprehensive cancer centres (CCCs), in ...
Voir le projet

 29

 TERMINÉ 

OncoTrack - Methods for systematic next generation oncology biomarker development (ONCOTRACK)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2016,

We propose here an exhaustive analysis of the genome, exome, methylome and transcriptome of primary tumours and metastases from patients with colon carcinoma, based on a combination of deep sequencing and chip based techniques. Dependent on their availability, we shall also perform analyses of tumor stem cells, circulating tumor cells, free tumor DNA in serum and xenografts derived from the same p ...
Voir le projet

 22

 TERMINÉ 

WINTHERapeutics: development of a systems biology method to predict efficacy of cancer drugs to optimize individualized therapeutic decision and improve clinical outcome for cancer patients (WINTHER)

Date du début: 1 mars 2013, Date de fin: 28 févr. 2015,

Relevance: WINTHER project focuses on the development and validation, in 24 months, of industry supported new tools and computational methods, to predict efficacy of drugs in cancer patientsCurrent medical needs: Selection of cancer targeted therapies based on molecular abnormalities (mutations /amplifications/ translocations) benefit today only to 10-40% of patients. For the remaining majority, ...
Voir le projet

 12

 TERMINÉ 

Modelling and predicting sensitivity to targeted therapies in colorectal cancers (COLTHERES)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2014,

Effective and long term treatment of cancer is now in sight, but will ultimately require an increasingly ‘personalised’ approach where the ‘right’ combination of drugs will be administered to the ‘right’ patients, based on a detailed understanding of their genetic background and their co-associated sensitivity or resistance ‘biomarkers’. Efforts are specifically required to identify validated risk ...
Voir le projet

 11

 TERMINÉ 

OVErcoming Resistance to anti-HER2 therapy (OVER-HER2)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2014,

"HER2 is a membrane receptor tyrosine kinase overexpressed in 30% of breast tumors and results in an aggressive clinical course. Anti-HER2 therapies including monoclonal antibodies (trastuzumab) and small-molecule tyrosine kinase inhibitors (lapatinib) are active and have improved survival of patients with HER2 overexpressing breast cancer. However, the emergence of primary or acquired resistance ...
Voir le projet

 2

 TERMINÉ 

Role of Notch signaling pathway in Glioma Stem Cells (Notch pathway in GSC)

Date du début: 1 juin 2012, Date de fin: 20 sept. 2014,

Glioblastoma multiforme (GBM) is the most common malignant intracranial tumor in adults. Despite the knowledge of the genetic alterations associated to GBM and the improvement in neurosurgery and chemo- and radiotherapy, little improvement has been achieved in the median survival. Recently, glioma stem cells (GSCs) have been identified to be responsible of the origin, recurrence and drug resistanc ...
Voir le projet

 2

 TERMINÉ 

Molecular Mechanisms of Glioma Genesis and Progression (Glioma)

Date du début: 1 août 2008, Date de fin: 31 juil. 2014,

Glioma is the most common and aggressive tumour of the brain and its most malignant form, glioblastoma multiforme, is nowadays virtually not curable. Very little is known about glioma genesis and progression at the molecular level and not much progress has been achieved in the treatment of this disease during the last years. The understanding of the molecular mechanisms involved in the biology of ...
Voir le projet

 3

 TERMINÉ 

Pathway-based Secretomes in Breast Cancer Biomarker Discovery (PathSec-BCa-BM)

Date du début: 1 mai 2010, Date de fin: 30 avr. 2014,

Improvements in the characterization of human tumors have resulted in better survival rates for cancer patients. However, less progress has been made in the development of clinical tools to monitor the course of the disease. Tumor markers have not had a broad acceptance in the clinical community, because the few that are known are organ rather than tumor specific. Proteomics biomarker discovery re ...
Voir le projet

 2

 TERMINÉ 

Targeting Cancer Stem Cells (CSC) for the development of more effective treatments to cure cancer patients (Anti-CSC)

Date du début: 1 déc. 2012, Date de fin: 30 nov. 2013,

Global cancer market is growing at a CAGR of 6.9% with an estimated value of $81bn in 2016. Although the huge R&D investment observed in the past years in the development of new treatments, there is still lack on an effective treatment in many tumour types. In particular, the median survival for glioblastoma multiforme (GBM), a high-grade brain tumour affecting 23,000 patients a year in US and EU, ...
Voir le projet

 2